Current treatment of diabetic nephropathy is effective; however, substantial gaps in care still remain and new therapies are urgently needed to reduce the global burden of the complication. Desirable properties of an "ideal" new drug should include: primary prevention of microalbuminuria, additive/synergistic anti-proteinuric effect in combination therapy with renin angiotensin system blockers, reduction of chronic kidney disease progression to lower the risk of end-stage renal disease, and cardiovascular protection. Growing evidence suggests that sodium-glucose cotransporter 2 inhibitors (SGLT2i) may fulfill many of these criteria and represent novel tools to cover the unmet needs in diabetic nephropathy care. However, the underlying mechanisms of SGLT2i renal benefits are still poorly understood and promising results from cardiovascular outcome trials with SGLT2i need confirmation in dedicated renal outcome trials.

SGLT2 inhibition to address the unmet needs in diabetic nephropathy

Barutta, F
Co-first
;
BERNARDI, SARA;Gargiulo, G;Durazzo, M;Gruden, G
Last
2019-01-01

Abstract

Current treatment of diabetic nephropathy is effective; however, substantial gaps in care still remain and new therapies are urgently needed to reduce the global burden of the complication. Desirable properties of an "ideal" new drug should include: primary prevention of microalbuminuria, additive/synergistic anti-proteinuric effect in combination therapy with renin angiotensin system blockers, reduction of chronic kidney disease progression to lower the risk of end-stage renal disease, and cardiovascular protection. Growing evidence suggests that sodium-glucose cotransporter 2 inhibitors (SGLT2i) may fulfill many of these criteria and represent novel tools to cover the unmet needs in diabetic nephropathy care. However, the underlying mechanisms of SGLT2i renal benefits are still poorly understood and promising results from cardiovascular outcome trials with SGLT2i need confirmation in dedicated renal outcome trials.
2019
35
1
13
GFR; SGLT2; albuminuria; diabetic nephropathy; experimental diabetes
Barutta, F; Bernardi, S; Gargiulo, G; Durazzo, M; Gruden, G
File in questo prodotto:
File Dimensione Formato  
Barutta_et_al-2019-Diabetes_Metabolism_Research_and_Reviews.pdf

Open Access dal 19/04/2020

Tipo di file: POSTPRINT (VERSIONE FINALE DELL’AUTORE)
Dimensione 1.08 MB
Formato Adobe PDF
1.08 MB Adobe PDF Visualizza/Apri
Barutta_et_al-2019-Diabetes_Metabolism_Research_and_Reviews.pdf

Accesso aperto

Tipo di file: PDF EDITORIALE
Dimensione 807.25 kB
Formato Adobe PDF
807.25 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1700251
Citazioni
  • ???jsp.display-item.citation.pmc??? 15
  • Scopus 26
  • ???jsp.display-item.citation.isi??? 19
social impact